Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great post. That's a scary assessment, but accurate. Can you post a link for where you found this? I did a quick Google search but couldn't find it. Thanks in advance either way.
Great find, Sushi! Thanks for posting!
Thank you so much for sharing this, Sushifishman-san. This is certainly exciting news. It will an interesting ride, for sure, as it has been here for several years for me.
*mmmhmhmhmmhmmhmbullshitmmhmhmhmhhmmmm* ...sorry. Sorry. Just was clearing my throat, had a little phlegm there... still shaking a cold...
Lightrock, thank you so much for your insight. Very interesting points that you are making.
I see it on my TD account. Sweet...
Yahoo Finance only shows BID of $8.90 and ASK of $9.31.
Is anyone else seeing this?!? Ameritrade shows the current ASK for CVM at $39.01, and the BID at $8.79. None of the other 19 biotechs on my watch list show any similar discrepancy to that extreme... It's probably nothing, given that it's a Sunday, but...???
New Insider Buying! Geert and Patricia Prichep bought more shares. Just out a few minutes ago.
Agreed. If data from the P3 shows real, significant improvement in survivability, but is just shy of the 10% goal, it's still a success. So do you think that, if that were the case, MK would still be a candidate for approval?
So, what would happen if the P3 study results showed only 9% increase, or 8.3%? While not the target goal, these slightly lower percentages would still represent a success, particularly vs some of the current treatments in use today. How would investors react? The medical community? Would it be the end of MK as a potential treatment?
This one is interesting, as well:
http://www.newsoracle.com/2016/09/12/analysts-estimates-and-ratings-novavax-inc-nasdaqnvax/
So now that Titan is included in the Russell 3000, and some of the tutes are likely to buy in, can we expect to see similar volatility in the share price over any given timeframe, i.e. day, week, etc.? Exclusive of external forces or general market volatility, I mean. Thoughts?
I would like to extend my sincerest thanks to everyone who frequents this board, but in particular: TRUTH, matthewverymuch, turks, Doctor Detroit, Rentier, tipdigger86, interstate, Rogerthat1, and bluejacket6 - your individual contributions to this board since I've been following it (starting early 2014) have been excellent, and the ongoing dialogue has been a tremendous part of my education and strategy development. I have only posted a few times, as I'm WAY out of my league here, but Titan was the first company I ever invested in back in 2011, and it's been a wild (and painful) ride. I'm glad I stayed the course, as I believe very much in the potential for Probuphine, and also in Pro Neura. I'm not just here for monetary gain, but for personal reasons, and today is a great day for all of us. All of you I mentioned have given me great advice at various times throughout the years. Thank you so very much for the articles, the constructive dialogue, and the countless perspectives. And to TRUTH especially, thank you, and congratulations. Congrats to all!
I agree 100%
Has anyone had trouble placing an order for TTNP online? I tried yesterday and today and got a message saying that I had to contact my broker to place the order. I use Scottrade. My broker saw that it was restricted, but said there were no obvious reasons why. Anyone else experiencing this?
I agree completely.
Does anyone know how many patients Geert said they might have to drop from the study? The ones who were enrolled by inVentiv? I think it was around 120. Why would those patients have to be dropped, anyway? Because of the lawsuit?
PUBLIC OFFERING
Bet this had something to do with the drop. How did they know? Maybe the arbitration isn't going so well?
VIENNA, Va.--(BUSINESS WIRE)--
CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) today announced that it has commenced an offering of common stock and warrants. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
Dawson James Securities, Inc. is acting as the sole placement agent for the proposed offering on a best efforts basis.
The offering will be made by CEL-SCI pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission (“SEC”) on July 8, 2014. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Copies of the complete preliminary prospectus related to the offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, mmaclaren@dawsonjames.com or toll free at 866.928.0928.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects” and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company’s ability to complete the proposed offering. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. CEL-SCI undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151022006652/en/
Contact:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
Personally, I'm getting a bit nervous about the arbitration. I've read everything I can find about it, and there are a lot of opinions for a favorable outcome for CVM. However, I can't help but think that, if Inventiv stands to lose, why they haven't settled yet. Even if they offered something lower and CVM refused it, if the case seems to be leaning heavily in favor of CVM, why not up the offering and avoid costly legal fees?
I wonder if they (Titan) want to wait until after the stockholder's meeting in August before they submit the NDA. I hope not, but submitting the NDA shortly after the meeting might help bolster any pps fallout that results from the meeting... Of course, it may be entirely up to Braeburn as to when the NDA is submitted. The tone from Braeburn's PR's and website info about Probuphine make it sound like they own it. They take all of the credit.
True, too true. Wonder if we'll get back to the .60's this week...
Powerful testimony, Truth. Thanks for sharing that.
I've been thinking the same thing. His average pps is $.64. Wonder how long he's planning to hold...
OTCShortReport shows that %58.68 of today's volume was shorts. That's incredible. Am I mistaken, or is this helping keep the share price down? I tried to place orders a few times today (I use Scottrade) but I couldn't because the Ask kept changing to 0.00. So I was effectively barred from purchasing stock.
MM's are seriously manipulating this stock today.
I agree, Kirbs. I would love for the price to drop below .6 again. Speculation alone will drive the share price up after the trial is complete, even before the results are released. Probably sooner. ...Of course, everything at this point is dependent on the trial results. Personally, I don't count on FDA approval of Probuphine as a done deal, but having researched Braeburn, I am glad that they are running the show. Their masters seem to feel Probuphine is worth the risk, and they seem to be well-organized. IF results are decent, there will be plenty of gains to be had from speculation driving up the price. I can't quite grasp the shorts, though, and how much negative pressure they are putting on the share price. There is a LOT of shorting going on with this stock.
According to otcshortreport.com, 50% of the volume today was shorts, 43% on Friday, and 40% on Thursday. How does this affect the share price? Does it keep the price artificially low? Does anyone expect a pullback this week?
Bluejacket 6,
thank you very much for your responses. Forgive me, but I don't have a paid subscription, so I'm not able to private message. In the future, feel free to email me at latemaven@gmail.com.
For the record, I have followed Titan since 2011, and I have been invested at various times. I am not currently invested here, but I intend to buy in very soon. I'm kind of hoping that, over the next few weeks/months, it will make it's way down to anywhere in the .60s, although I know that this could be a dream never realized. If it's not there or nearly there at a certain time, I'll go ahead and buy in. I actually think that any pps under $1 is golden, but I'd like to get as much mileage as possible here. It will have to be a long and patient investment, to be sure, but I don't currently know of any "risky" stocks that are as sure of a bet as Titan is. I'm willing to invest and wait, because the potential here is so great.
Also, I want to support the work that Titan is doing, because I work in an ER and other medical facilities, and given various job-related experiences, I believe that the need for an implantable, constant-release form of Buprenophine is needed more now than ever. Widespread addiction to opiate-derived medications notwithstanding, cheap Heroin is flooding the U.S. from exterior cartels who are converting considerable percentages of their sales from marijuana to heroin, as they are looking ahead and foreseeing diminishing returns from black-market marijuana sales. Thus, cases of heroin addiction are drastically increasing over much of the country, as a steady and "affordable" supply is causing heroin to overtake meth as the addiction of choice. The need here is too great, the facts are clear, and I don't believe that the FDA will deny the next application, assuming that results from this next trial are similar to the previous Phase III trial.
Concerning Braeburn, I can't help but suspect that it has at least considered buying a controlling stake in Titan. If I understand correctly, when the agreement between the two companies was amended after the FDA's rejection, Titan was given a higher royalty from gross sales than in the original agreement, as well as royalties from other "addiction treatments" that Braeburn might acquire elsewhere, while retaining the sole rights to sales of Probuphine generated outside of the U.S. (or maybe it's outside of North America). Given those concessions, and the expense that Braeburn has taken on by agreeing to provide the capital for the new trial, it would certainly be reasonable to expect Braeburn to make the move to buy a controlling interest in Titan. What do they have to lose? They would essentially be getting back at least some of what they pay to Titan once Probuphine is licensed and is generating sales. Then, too, Braeburn would gain from profits generated from Titan's revenue generated outside of the U.S., which is not in the current agreement. While I may be mistaken, I'm under the impression that Braeburn currently owns 11% of Titan. Regardless of whether or not Braeburn buys a "controlling interest", it would do well to increase it's position before a license is granted, because the increase in share price will help offset the expenses from the second Phase III trial. Furthermore, if Braeburn's current pps of Titan stock is in the upper .90s (as reported by the Seeking Alpha article that I read earlier this summer, which I found to be convincingly thorough), I would think that Braeburn would acquire more shares of Titan before the share price goes higher, assuming they can do so legally.
However, I am not a business guru, and I still have some DD to do. Any thoughts, contrary or otherwise, are always appreciated.
GLTA
Greetings TTNP Investors.
I have been following TTNP on and off for a few years, but have only recently discovered this message board. I was absolutely shocked by the FDA's rejection of Probuphine in April of 2013, which seems to be a common sentiment here. I was just wondering if anyone had any thoughts about Braeburn's motives regarding the future of Titan. Given that Braeburn already owns a significant percentage of Titan's shares, does anyone suspect that Braeburn will make a move to acquire a controlling interest in TTNP? I read an interesting article by a contributor to Seeking Alpha earlier this year, in which the author supplied Braeburn's pps at 96 or 98 cents. He suggested that Braeburn might be interested in acquiring a controlling interest in Titan. If I have read the PR correctly, the most recent amendment of the agreement between the two companies actually sweetened the deal for Titan in exchange for more of its shares given to Braeburn. If this is correct, then it certainly would be in Braeburn's interest to acquire more of Titan's shares. Futhermore, I would think that, if Braeburn were to seek such a move, it would 1) do so before the share price of Titan increased above Braeburn's current pps, and 2) doing so would positively affect Titan's share price.
I realize that I'm stepping into a conversation that I have not been participating in, so please forgive me if these topics have already been spun into yarn. Also, I am in the process of redoubling my efforts at conducting DD as time permits, but I am admittedly somewhat behind the times. Not asking for anyone else's DD here in order to avoid investing my own time into the research, just wanted some opinions as to Braeburn's motives in the near future with Titan.
Any thoughts? Thanks in advance for any responses.
Buying more now! Get it while you can!!!
WOOO HOOOOOO!!!!!
HOLY SH%&!!! The community speaks for us!!!!
An EXCELLENT description by DP!
Looking REALLY good here
It sounded to me like the last representative spoke, there were no objections, and then the council voted to pass. Is that right? Is it going that fast? Could be good news for us if so.
Great post! Thank you so much, that is very helpful.
How many cutivation and production licenses will be issued by the Clark County council? I can't find a solid number in any of my DD.
Is there a reliable source that anyone can post which gives the number of cultivation and production licenses that will be awarded by the Clark Co. council? I've been looking but have not been successful. I think I saw posted on here over the weekend that over 60 cultivation licenses were up for grabs, but that seems rather "high" to me...